Onconetix Stock Today
| ONCO Stock | USD 0.60 0.09 12.94% |
Performance0 of 100
| Odds Of DistressOver 85
|
Onconetix is selling at 0.6007 as of the 2nd of December 2024; that is 12.94 percent decrease since the beginning of the trading day. The stock's open price was 0.69. Onconetix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Onconetix symbol was changed from BWV on 22nd of December 2023. Equity ratings for Onconetix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 13th of December 2022 and ending today, the 2nd of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of February 2022 | Category Healthcare | Classification Health Care |
Oncology Med, Inc. offer full service cancer center solutions. The company has 8.29 M outstanding shares of which 33.33 K shares are now shorted by private and institutional investors with about 0.45 trading days to cover. More on Onconetix
Moving together with Onconetix Stock
Moving against Onconetix Stock
Onconetix Stock Highlights
| Older Symbol | BWV | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, OMX Stockholm, OMX Stockholm Small, OMX Stockholm GI, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Onconetix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Onconetix's financial leverage. It provides some insight into what part of Onconetix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Onconetix (ONCO) is traded on NASDAQ Exchange in USA. It is located in 201 East Fifth Street, Cincinnati, OH, United States, 45202 and employs 12 people. Onconetix was previously known as BWV and was traded on NASDAQ Exchange under the symbol BWV. Onconetix is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.72 M. Onconetix conducts business under Biotechnology sector and is part of Health Care industry. The entity has 8.29 M outstanding shares of which 33.33 K shares are now shorted by private and institutional investors with about 0.45 trading days to cover.
Onconetix currently holds about 113.36 K in cash with (13.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Onconetix Probability Of Bankruptcy
Ownership AllocationOnconetix has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Onconetix Ownership Details
Onconetix Historical Income Statement
Onconetix Stock Against Markets
Onconetix Corporate Management
| MD MBA | Chief Officer | Profile | |
| Christian Bruhlmann | Chief Officer | Profile | |
| Dr Very | Senior Development | Profile | |
| Theodore Yoho | Head Development | Profile | |
| Erin Henderson | Consultant | Profile | |
| Brian Price | Head Strategy | Profile | |
| Ali Fattom | Head Discovery | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (109.20) | Revenue Per Share 2.892 | Return On Assets (0.22) | Return On Equity (17.58) |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.